Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oxpentifylline in dementia: a controlled study.

K Ghose

    Archives of Gerontology and Geriatrics
    |April 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Oxpentyifylline showed potential benefits for multi-infarct dementia (MID) patients, improving their mental state. However, no significant effects were observed in primary degenerative dementia (PDD) patients, suggesting further research is needed.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Diphtheria in an Unusual Location.

    The Indian medical gazette·2017
    Same author

    Interactions of amitriptyline with guanethidine and thymoxamine in the human iris.

    British journal of clinical pharmacology·2012
    Same author

    Correlation of pupil reactivity to tyramine or hydroxyamphetamine and tyramine pressor responses in patients treated with amitriptyline or mianserin.

    British journal of clinical pharmacology·2012
    Same author

    The assessment of interactions in man between tyramine and viloxazine hydrochloride, an antidepressant drug.

    British journal of clinical pharmacology·2012
    Same author

    Free-flight encounters between praying mantids (Parasphendale agrionina) and bats (Eptesicus fuscus).

    The Journal of experimental biology·2008
    Same author

    Mode of action and adverse effects of lipid lowering drugs.

    Drugs of today (Barcelona, Spain : 1998)·2004
    Same journal

    Corrigendum to "Updating knowledge on existing approaches on advanced care planning interventions: An umbrella review" [Archives of Gerontology and Geriatrics 148 (2026) 106255].

    Archives of gerontology and geriatrics·2026
    Same journal

    Exercise-responsive Wnt/β-catenin signaling across metabolic tissues during aging: A narrative review.

    Archives of gerontology and geriatrics·2026
    Same journal

    Attention as a potentially responsive cognitive outcome in a community-based multidomain dementia prevention program (the community-adapted J-MINT Brain Health Program in Kikuyo Town, Japan).

    Archives of gerontology and geriatrics·2026
    Same journal

    Trajectories of physical function during a 12-week resident-led health promotion program (HATSURATSU) among community-dwelling older adults in Japan.

    Archives of gerontology and geriatrics·2026
    Same journal

    Acute confusional states and functional recovery after West Nile virus infection in hospitalized older adults.

    Archives of gerontology and geriatrics·2026
    Same journal

    Kinestesia: A neuroplasticity-based cognitive-motor intervention for brain health in aging-proof-of-concept pilot evidence.

    Archives of gerontology and geriatrics·2026
    See all related articles

    Area of Science:

    • Gerontology
    • Neurology
    • Pharmacology

    Background:

    • Dementia, including primary degenerative dementia (PDD) and multi-infarct dementia (MID), significantly impacts cognitive function.
    • Investigating pharmacological interventions to improve mental state in dementia patients is crucial.

    Purpose of the Study:

    • To evaluate the efficacy of oxpentifylline in improving the mental state of patients with PDD and MID.
    • To compare the effects of oxpentifylline versus placebo in a double-blind study.

    Main Methods:

    • A 12-week double-blind study involving 36 patients (aged 60-88) with PDD or MID.
    • Patients received either 400 mg oxpentifylline thrice daily or a placebo.
    • Cognitive function was assessed using Folstein's mini mental state (FMMS) and Sandoz Clinical Assessment Geriatric Scale (SCAGS).

    Related Experiment Videos

    Main Results:

    • No significant overall drug-related improvement in mental state was observed for either dementia type.
    • Multi-infarct dementia (MID) patients receiving oxpentifylline showed a statistically significant improvement compared to placebo (p < 0.05).
    • No similar benefit was found in primary degenerative dementia (PDD) patients treated with oxpentifylline.

    Conclusions:

    • Oxpentyifylline may offer a potential benefit specifically for patients with multi-infarct dementia (MID).
    • Further long-term studies with larger patient cohorts are necessary to confirm these findings.
    • The haemorrheological agent oxpentifylline's efficacy appears limited to specific dementia subtypes.